# Shanghai OPM Biosciences

Shanghai OPM Biosciences is a Corporate Investor based in Shanghai, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Shanghai, China
- **Region:** Asia
- **Address:** Building 28, Lane 908, Ziping Road, Pudong New Area, Shanghai, 201321, China
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** opmbiosciences.com
- **LinkedIn:** https://www.linkedin.com/company/opm-bio

## Regulatory record

- **Reports private funds:** No

## About

Founded in 2013 by Zhihua Xiao, Shanghai OPM Biosciences operates as a corporate investor structured around two interdependent pillars: cell culture media development and end-to-end CDMO services. The company maintains its headquarters and a GMP workshop in Shanghai’s Pudong New Area, alongside a Zhangjiang Science City CDMO platform, and opened a North American facility in Pleasanton, California. Xiao, the firm’s chairman and general manager, shares control with deputy general manager Yunfen He, who also serves as president of the US entity. OPM’s model compresses the biologics development timeline — from cell line engineering and media optimization to clinical GMP production — with a China-based footprint that also services US clients. Its operating assets include an industrial GMP workshop on Ziping Road, a CDMO platform in Zhangjiang Science City, and a commercial office in Pleasanton, California. The company deploys capital through its integrated Shanghai manufacturing and Zhangjiang CDMO infrastructure, while the Pleasanton office extends its service reach to North American biopharma clients. Xiao and He control the firm jointly, with He leading US business development. OPM’s collaboration map includes Sequoia Capital China and GL Ventures, which co-invested in PharmaLegacy alongside the OPM network. OPM is unusual among biopharma asset owners because it is not a venture fund, a family office, or a pure-play manufacturer — it functions as a dual-operating company that uses its cell culture media business to feed its CDMO pipeline.

## Sectors

- Digital Health

## Offices

- Pleasanton, California, United States

## People

- Zhihua Xiao — Chairman, General Manager
- Yunfen He (Fiona He) — Deputy General Manager, President of OPM US

## Questions

### Who controls Shanghai OPM Biosciences?

Zhihua Xiao, the founder, serves as Chairman and General Manager and is the actual controller of the firm. His spouse, Yunfen He (Fiona He), is a co-controller, Deputy General Manager, and President of OPM’s US subsidiary. The two jointly control the company.

### How does OPM differ from a standalone CDMO?

OPM is an integrated cell culture media producer and CDMO, not an outsourced manufacturer alone. It develops and sells its own media formulations while providing process development and GMP production, giving it a captive demand pipeline that traditional CDMOs must secure from external customers.

### Does OPM operate outside China?

Yes. OPM maintains a North American facility at 5653 Stoneridge Drive in Pleasanton, California, led by Yunfen He in her role as President of OPM US. This office extends the firm’s CDMO and media services to US-based biopharma companies.

### What does OPM's Shanghai manufacturing footprint include?

Shanghai operations consist of a headquarters and GMP workshop located on Ziping Road in Pudong New Area, plus a CDMO platform situated in Zhangjiang Science City. These facilities support cell line development, media manufacturing, and clinical-to-commercial bioprocessing.

## Related profiles

- [Open Source Securities](https://altss.com/profile/shanghai-open-source-sichuang-investment)
- [Shanghai Private Equity Association](https://altss.com/profile/shanghai-private-equity-association)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/shanghai-opm-biosciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology